EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

Inclusion criteria

• 1 prescription(s) fill for BGF on or following July 24, 2020 (date of BGF approval in the United States)

• Patients must have evidence a qualifying exacerbation events which, per local or global guidelines, would qualify a patient to have treatment escalated or initiated to triple therapy. The qualifying exacerbation event must occur within the 12-month period preceding the initiation of BGF but occurring on or following local BGF commercial availability (July 24, 2020) and includes either of the following
• 12 months of continuous health plan enrollment preceding the qualifying index exacerbation event date ('baseline' period)
• 1 day of continuous enrollment following the qualifying index exacerbation date

• Age ≥ 40 years on the qualifying index exacerbation event

Exclusion criteria

• Presence of cancer diagnoses other than basal or squamous cell skin cancer during the baseline or follow-up periods
• Presence of interstitial fibrosis, sarcoidosis, or pulmonary embolism diagnoses during the baseline or follow-up periods
• Presence of triple therapy SITT during the baseline period through BGF initiation